Join the club for FREE to access the whole archive and other member benefits.

CRISPR Therapeutics

Company developing transformative gene-based medicines for serious human diseases

We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases

Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.

Visit website: http://www.crisprtx.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

CRISPR Therapeutics News

CRISPR's gene editing therapy finds cure for blood cancer

STAT - 05-Dec-2020

Early data from Vertex & CRISPR showed promising results to cure blood disorders

Read more...

Company introduces 'gene writing', to surpass CRISPR's limitations

Wired - 07-Jul-2020

New class of gene editors set to remove hurdles of traditional gene therapy

Read more...

CRISPR gene editing to cure beta thalassaemia and sickle cell disease

New Scientist - 12-Jun-2020

Didn't change the inherited faulty gene, but gene to switch on fetal haemoglobin production

Read more...

First attempt to use CRISPR tool to treat a genetic disorder

NPR - 29-Jul-2019

Cells are being taken from patients' bone marrow and genetically modified with CRISPR

Read more...

Gene Therapies to Greatly Reduce the Incidence of Cardiovascular Disease

Fight Aging! - 09-Mar-2018

Gene therapy could disable genes that sustain levels of lipids in the bloodstream. Number of cre...

Read more...